# OCULAR THERAPEUTIX, INC (OCUL) · Edgar & Edgarette company card

> Ocular Therapeutix (OCUL) saw revenue fall 18.5% in FY2025 to $52 million, operating margin -520% against a -3.8% median for pharmaceutical preparations, equity 81.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1393434 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/OCUL) · [JSON](https://www.pops4.com/boards/company/OCUL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $52M |
| Revenue growth, 1 year | -18.5% |
| Revenue growth per year | 4.5% |
| Operating margin | -519.8% (prior year -269.6%) |
| Net margin | -511.9% |
| Operating cash flow | −$205M |
| Capital spending | $12M |
| Free cash flow | −$217M |
| Cash | $737M |
| Long-term debt | — |
| Total assets | $808M |
| Total equity | $654M |
| Equity ÷ assets | 81.0% |
| Return on equity | -40.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 3.49 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.95 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -519.8% in FY2025; revenue is hard to predict: its 80% range is ±61%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $52.0M (FY2025). Experience: revenue down 18.5% on the year, up 4.5% a year over 4 years; operating margin -519.8%, down from -269.6%. Soundness: equity 81.0% of assets, return on equity -40.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $22.1M and $92.1M next year (method v4.1: its own 5-year record of growth weighed at 57% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $23.3M to $87.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -519.8% against a -3.8% median; growth -18.5% against 13.7%.

Range logged 2026-10-19, receipt dffc3f37ce108dc5, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-11-09 ([filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124159/0001104659-26-124159-index.htm))

## Recent filings

- 8-K · filed 2026-11-09 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124159/0001104659-26-124159-index.htm)
- 10-Q · filed 2026-11-09 · [filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124155/0001104659-26-124155-index.htm)
- 8-K · filed 2026-11-09 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/0001104659-26-124151-index.htm)
- 8-K · filed 2026-10-16 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926116617/0001104659-26-116617-index.htm)
- 10-Q · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/0001104659-26-089450-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/0001104659-26-089443-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001393434.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1393434

## Cite

POPS4, Edgar & Edgarette: OCULAR THERAPEUTIX, INC (OCUL) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/OCUL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

